SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oxford GlycoSciences Plc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dalroi who wrote (44)8/23/2000 7:24:14 AM
From: nigel bates   of 469
 
From FT Marketwatch -

"...Lehman called its Wednesday morning rebuttal note "Storm in A Tea Cup", and says the criticisms of OGS's drug against the metabolic disorder Gaucher's disease are not new.
Lehman also says it expects OGS to pick up new customers for its protein analysis technology.
Lehman reiterated its buy rating on OGS and its 2600 pence price target."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News